Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2013 1
2014 2
2015 3
2016 2
2017 2
2018 1
2020 4
2021 2
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
The May-Hegglin anomaly.
Filanovsky K, Shvidel L, Vorst E, Berrebi A, Shtalrid M. Filanovsky K, et al. Eur J Haematol. 2009 Oct;83(4):390. doi: 10.1111/j.1600-0609.2009.01286.x. Epub 2009 Jun 2. Eur J Haematol. 2009. PMID: 19500132 No abstract available.
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I, Perry C, Segman Y, Amit O, Bar-On Y, Katz OB, Gold R, Ribakovsky E, Avigdor A, Vainstein V, Goldschmidt N, Ringelstein-Harlev S, Horowitz NA, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Vezker M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Luttwak E, Herishanu Y, Ram R. Avivi I, et al. Among authors: filanovsky k. Ann Hematol. 2022 Apr;101(4):755-762. doi: 10.1007/s00277-021-04749-9. Epub 2022 Jan 27. Ann Hematol. 2022. PMID: 35083525
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panagiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Hoeks M, et al. Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32948844 Free PMC article. No abstract available.
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Vainstein V, Avni B, Grisariu S, Kfir-Erenfeld S, Asherie N, Nachmias B, Auman S, Saban R, Zimran E, Assayag M, Filanovsky K, Horowitz NA, Lebel E, Shaulov A, Gur M, Rosenbluh C, Krichevsky S, Stepensky P, Gatt ME. Vainstein V, et al. Among authors: filanovsky k. Cancers (Basel). 2023 Jul 3;15(13):3471. doi: 10.3390/cancers15133471. Cancers (Basel). 2023. PMID: 37444582 Free PMC article.
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Segman Y, Ribakovsky E, Avigdor A, Goldhecht Y, Vainstein V, Goldschmidt N, Harlev S, Horwitz N, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Zektser M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Herishanu Y, Ram R, Perry C, Avivi I. Segman Y, et al. Among authors: filanovsky k. Leuk Lymphoma. 2021 Jan;62(1):118-124. doi: 10.1080/10428194.2020.1824069. Epub 2020 Sep 27. Leuk Lymphoma. 2021. PMID: 32981410
23 results